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MouseThe cells of the second heart ﬁeld (SHF) contribute to the outﬂow tract and right ventricle, as well as to parts
of the left ventricle and atria. Isl1, a member of the LIM-homeodomain transcription factor family, is
expressed early in this cardiac progenitor population and functions near the top of a transcriptional pathway
essential for heart development. Isl1 is required for the survival and migration of SHF-derived cells into the
early developing heart at the inﬂow and outﬂow poles. Despite this important role for Isl1 in early heart
formation, the transcriptional regulation of Isl1 has remained largely undeﬁned. Therefore, to identify
transcription factors that regulate Isl1 expression in vivo, we screened the conserved noncoding sequences
from the mouse Isl1 locus for enhancer activity in transgenic mouse embryos. Here, we report the
identiﬁcation of an enhancer from the mouse Isl1 gene that is sufﬁcient to direct expression to the SHF and its
derivatives. The Isl1 SHF enhancer contains three consensus Forkhead transcription factor binding sites that
are efﬁciently and speciﬁcally bound by Forkhead transcription factors. Importantly, the activity of the
enhancer is dependent on these three Forkhead binding sites in transgenic mouse embryos. Thus, these
studies demonstrate that Isl1 is a direct transcriptional target of Forkhead transcription factors in the SHF and
establish a transcriptional pathway upstream of Isl1 in the SHF.© 2009 Elsevier Inc. All rights reserved.IntroductionThe cardiac progenitors that give rise to the outﬂow tract, right
ventricle, and portions of the atria are distinct from the progenitors
that form the left ventricle (Buckingham et al., 2005). Fate-mapping
studies in avian and mouse systems have demonstrated that the cells
that comprise the outﬂow tract region and the right ventricle
originate from an extra cardiac progenitor population that resides in
the pharyngeal mesoderm adjacent to the pharyngeal endoderm (Cai
et al., 2003; Kelly et al., 2001; Mjaatvedt et al., 2001; Waldo et al.,
2001). This population of cells, referred to as the second heart ﬁeld
(SHF), is progressively added to the growing linear heart tube at the
outﬂow and inﬂow poles of the heart (Black, 2007; Buckingham et al.,
2005). The linear heart tube forms from the classical cardiac crescent,
also referred to as the ﬁrst heart ﬁeld (FHF), and the existence of an
extra cardiac population of progenitor that contributes to the outﬂow
tract and right ventricle provides an embryological explanation for the
longstanding observations that many genes and transgenes exhibit
regionally restricted expression within the heart along these bound-
aries (Black, 2007; Buckingham et al., 2005).l rights reserved.A subset of the SHF, referred to as the anterior heart ﬁeld (AHF),
speciﬁcally contributes to the outﬂow tract and right ventricle and is
deﬁned in mice by the expression of an Fgf10 transgene, as well as by
the expression of aMef2c-AHF-lacZ transgene (Kelly et al., 2001; Verzi
et al., 2005). The broader SHF has been deﬁned by the expression of
the Isl1 gene, which encodes a LIM-homeodomain protein essential
for cardiac development (Cai et al., 2003). Isl1 expression is detected
very early at the cardiac crescent stage, contiguous with, but medial
and dorsal to mlc2a-positive cells of the FHF (Cai et al., 2003).
Following ventral morphogenesis of the mouse embryo, Isl1+ cells are
present in the pharyngeal and splanchnic mesoderm, as well as in the
foregut endoderm (Cai et al., 2003). Lineage tracing analyses show
that Isl1 descendants contribute extensively to the heart including to
parts of the inﬂow tract region, the atria, and the left ventricle, as well
as the outﬂow tract and the right ventricle (Cai et al., 2003). In
addition, Isl1+ splanchnic mesoderm cells contribute to the bran-
chiomeric skeletal muscles in the head (Nathan et al., 2008). Recent
lineage analyses using Isl1-Cre activation of a conditional lacZ reporter
knocked in to the Gata4 locus suggested a substantially broader Isl1
expression domain than previously reported using standard Rosa26R
Cre-activated reporters (Ma et al., 2008).
Inactivation of Isl1 in mice results in growth arrest at embryonic
day (E) 9.5, and Isl1 knockout mice display profound defects in heart
development, including a failure to undergo looping morphogenesis
514 J. Kang et al. / Developmental Biology 334 (2009) 513–522and the apparent absence of complete segments of the heart (Cai et al.,
2003). It was suggested that defective heart formation in Isl1 knockout
mice is at least partially caused by aberrant proliferation of the
pharyngeal mesoderm, ultimately resulting in failed migration of Isl1-
expressing cells into the heart (Cai et al., 2003). Recent studies using
genetic marking of Isl1+ progenitors demonstrated that embryonic
Isl1-expressing cells are multipotent cardiac progenitors that give rise
to three cardiac lineages, including cardiomyocytes, smooth muscle,
and endothelial cells (Laugwitz et al., 2005; Moretti et al., 2006). In
addition to thosemajor cardiac lineages, it was recently suggested that
Isl1 and Nkx2.5-expressing progenitors also contribute to proepicar-
dium during heart morphogenesis (Zhou et al., 2008). However, in
spite of its essential role in cardiac development, the regulation of Isl1
transcription in the SHF remains largely undeﬁned.
Several transcription factors in addition to Isl1 have also been
implicated in the transcriptional regulatory program controlling SHF
development (Black, 2007). These include the MADS domain
transcription factor MEF2C, the bHLH transcription factor HAND2,
and the T-box transcription factors TBX20 and TBX1 (Black, 2007;
Takeuchi et al., 2005; Xu et al., 2004).
Several members of the Forkhead transcription factor family have
also been implicated in early cardiovascular development (Papanico-
laou et al., 2008). The Forkhead family of transcription factors consists
of 39 distinct members in humans, and members of this family are
involved in many diverse biological processes (Carlsson and Mahla-
puu, 2002; Lehmann et al., 2003). Foxa2 is expressed in the anterior
primitive streak and the node as early as E6.5 in the mouse
(Monaghan et al., 1993; Sasaki and Hogan, 1994). In addition, Foxa2
regulates Tbx1 in the SHF, suggesting a role for this Forkhead factor in
the transcriptional program controlling the development of the SHF
and its derivatives (Hu et al., 2004; Maeda et al., 2006; Yamagishi et
al., 2003). Foxf1 mutant mice die by E8.0 due to extraembryonic
mesoderm defects, consistent with the observation that Foxf1
expression is induced during gastrulation at E6.5 in the mesoderm
in mice (Kalinichenko et al., 2003; Mahlapuu et al., 2001; Peterson et
al., 1997). The broad expression of Foxf1 in the early mesoderm is
consistent with a possible role for this transcription factor in
establishing cardiovascular progenitor identity in the early lateral
mesoderm. Likewise, Foxc1 and Foxc2 are expressed in the SHF at the
cardiac crescent stage (E7.75 in mouse) and may play a role in
establishing identity of cardiovascular progenitors (De Val and Black,
2009; Seo and Kume, 2006). Knockout of either Foxc1 or Foxc2 in the
mouse results in perinatal lethality with a spectrum of cardiovascular
defects, including aberrant formation of the aortic arches, ventricular
septal defects, and abnormal semilunar valves (Winnier et al., 1999).
Importantly, compound Foxc1/Foxc2 homozygous mutants die much
earlier with more severe cardiovascular defects, including lack of the
outﬂow tract and right ventricle, suggesting that these two factors
have overlapping and dose-dependent roles in cardiovascular devel-
opment (Kume et al., 2001; Seo and Kume, 2006). FoxH1 has also been
demonstrated to play a key role in SHF development (von Both et al.,
2004). Foxh1 null mice fail to form AHF-derived structures, such as the
outﬂow tract and right ventricle, but normally form inﬂow and atrial
regions (von Both et al., 2004), suggesting a role restricted to anterior
regions of the SHF for this member of the Forkhead factor family.
Despite the identiﬁcation of multiple transcription factors involved
in SHF development, few regulatory relationships among those factors
have been identiﬁed. It has been established thatMef2c functions as a
downstream transcriptional target of Isl1 in the SHF, but the upstream
regulators of Isl1 in the SHF are essentially unknown. In the present
study, we identiﬁed an enhancer from the mouse Isl1 gene that is
sufﬁcient to direct expression to the SHF. This evolutionarily
conserved Isl1 enhancer is active in the cardiac crescent by E7.0 and
in the pharyngeal mesoderm and outﬂow tract by E8.5 in the mouse.
The Isl1 SHF enhancer contains three evolutionarily conserved
Forkhead binding sites that are efﬁciently bound by several relevantcandidate Forkhead proteins in vitro, and the Isl1 Forkhead sites are
required for enhancer activity in the pharyngeal mesoderm in
transgenic mouse embryos. Thus, these studies demonstrate an
important role for Forkhead transcription factors in the regulation of
Isl1 in the SHF.
Materials and methods
Cloning and mutagenesis
The 3642-bp Isl1-F fragment was generated by PCR from SV129Ev
mouse genomic DNA using the following primers: 5′-cctctcgagact-
cagttttgagca-3′ and 5′-ctcaggggatgtaaaagcttttc-3′. This fragment was
then cloned as an XhoI–SspI fragment into the XhoI and SmaI sites of
the transgenic reporter plasmid HSP68-lacZ (Kothary et al., 1989).
Deletion fragments of the Isl1-F enhancer were generated by digestion
and subsequent subcloning back into the corresponding sites of
HSP68-lacZ, using the following restriction sites: Isl1-F1, XhoI–EcoRV;
Isl1-F2, EcoRV–DraI. For Isl1-F3, Isl1-F-HSP68-lacZ was cleaved with
AseI and SalI and the Isl1-F3-HSP68-lacZ transgene fragment was
directly puriﬁed for oocyte microinjection. To generate the Isl1-
F2Δ298 fragment, the Isl1-F fragment was mutated to create a PstI
restriction site at nucleotides 2077–2082 of the Isl1-F fragment,
followed by cleavage with NsiI and PstI and subsequent re-ligation to
excise 298 bp in between the native NsiI site and the engineered PstI
site. The following mutant sequences were introduced sequentially
into Isl1-F2 to create the triple FOX mutant: mFOX1, 5′-gggctaatccctg-
cagggcgcttgac-3′; mFOX2, 5′-cagaccgcacaggagctccagcaccttt-3′;
mFOX3-3, 5′-tccctttggatggtacctcttgtttcaa-3′. The entire sequence of
the triple FOX mutant Isl1-F2 fragment was conﬁrmed by sequencing
on both strands.
Generation of transgenic mice
Transgenic reporter fragments were digested from the HSP68-lacZ
plasmid backbone, gel puriﬁed, and suspended in 5 mM Tris–HCl,
0.2 mM EDTA, pH 7.4, at a concentration of 2 μg/ml for pronuclear
injection. Transgenic embryos or stable lines were generated as
described previously (Rojas et al., 2005). DNA was extracted from
the yolk sac of embryos or from tail biopsies frommice by digestion in
tail lysis buffer (100mMNaCl, 25mMEDTA,1% sodiumdodecyl sulfate,
10 mM Tris–HCl, 200 μg/ml proteinase K, pH 8.0) at 56 °C overnight,
followed by genomic DNA extraction, restriction digestion, and
Southern blotting using standard methods. Embryos collected at E8.5
and earlier were genotyped by PCR, using the lacZ primers LACZ5 (5′-
cggtgaatggtgctgcgttgga-3′) and LACZ3 (5′-accaccgcacgatagagattc-3′).
All experiments using animals complied with federal and institutional
guidelines.
X-gal staining, in situ hybridization, and immunoﬂuorescence
β-galactosidase expression in transgenic embryos was detected by
X-gal staining, performed as described previously (Dodou et al.,
2003). Sections from X-gal-stained embryos and tissues were
prepared and counterstained with Neutral Fast Red, as described
previously (Anderson et al., 2004). Whole-mount in situ hybridization
of mouse embryos was performed exactly as described previously
(Rojas et al., 2005). Following hybridization, embryos were washed
and treated with RNaseA, as described previously (Wilkinson and
Nieto, 1993). Signal was detected using an alkaline phosphatase-
conjugated anti-digoxigenin antibody and BM purple alkaline phos-
phatase substrate (Roche Pharmaceuticals). Isl1 antisense probe was
generated from a pBluescript(SK)II+ plasmid containing the mouse
Isl1 cDNA linearized with XhoI and transcribed with T3 polymerase.
For detection of β-galactosidase and Isl1 proteins in mouse
embryos by immunoﬂuorescence, lacZ transgenic embryos were
Fig. 1. Schematic representation of part of the Isl1 locus and the Isl1-F transgene. The
top line represents an approximately 18-kb region of the mouse Isl1 locus, including
its six exons (black boxes). Exon 1 is the ﬁrst coding exon. Exon 6 contains the
translational stop codon and 3′ untranslated region. The Isl1-F enhancer is represented
as a red box in the upper diagram. The lower schematic depicts the transgene construct
Isl1-F-lacZ, which contains the 3642-bp Isl1-F fragment in the transgenic reporter
plasmid HSP68-lacZ.
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phosphate buffered saline (PBS), pH 7.4. Fixed embryos were infused
in series of sucrose solutions (15% and 30% sucrose in PBS) for 30 min
each, and then were frozen in 100% OCT compound (Tissue Tek II) on
dry ice and cryosectioned at a thickness of 10 μm. Sections were stored
at −80 °C until use. Sections were analyzed for Isl1 and β-
galactosidase protein expression using rabbit anti-β-galactosidase
(ICN) diluted 1:500 and mouse anti-Isl1 (Developmental Studies
Hybridoma Bank, Iowa City) diluted 1:100 in blocking solution
(5% normal goat serum and 5% non-fat powdered milk). Binding of
anti-β-galactosidase and anti-Isl1 primary antibodies was detected
using Oregon Green-conjugated goat anti-rabbit and Alexa Fluor 594-
conjugated goat anti-mouse secondary antibodies (Molecular Probes),
each diluted 1:200 in blocking solution.
Electrophoretic mobility shift assay (EMSA)
Double-stranded oligonucleotides were labeled by ﬁlling in over-
hanging 5′ ends with Klenow in the presence of 32P-dCTP. Labeled
probes were then puriﬁed on a nondenaturing polyacrylamide-TBE
gel. Binding reactions were conducted with recombinant Forkhead
proteins at room temperature in 1× binding buffer (40mMKCl,15mM
HEPES, pH 7.9, 1 mM EDTA, 0.5 mMDTT, 5% glycerol) with 1 μg of poly
dI–dC as a non-speciﬁc competitor, and competitor DNA as described
previously (Rojas et al., 2005). Recombinant FoxF1, FoxA2, FoxC2, and
FoxH1 were synthesized using the TNT Quick Coupled Transcription/
Translation Systems, as described in the manufacturer's directions
(Promega).
FoxF1 proteinwas generated from plasmid pCITE-FoxF1, which has
been described previously (Rojas et al., 2005). FoxA2 protein was
generated from plasmid pcDNA1-FoxA2, which was made by cloning
the mouse Foxa2 cDNA as an EcoRI–XbaI fragment into the EcoRI and
XbaI sites of pcDNA1/amp (Invitrogen). FoxC2 and FoxH1 proteins
were generated from their respective mouse cDNAs cloned into
plasmids pCR2.1-TOPO-FoxC2 and pCR2.1-TOPO-FoxH1. The
sequences of the control FoxF1, FoxA2, FoxC2, and FoxH1 binding
sites have been described previously (Overdier et al., 1994; Peterson
et al., 1997; Pierrou et al., 1994).
The sense-strand sequences of the oligonucleotides encompassing
the Forkhead sites from Isl1-F2 used for EMSA were: FOX1, 5′-
ggggagggctaatccaaacaaggcgcttgacttg-3′; mFOX1, 5′-gggctaatccctg-
cagggcgcttgac-3′; FOX2, 5′-ggtgcgcagaccgcacagcaaacacagcacctttagc-3′;
mFOX2, 5′-cagaccgcacaggagctccagcaccttt-3′, FOX3, 5′-ggtcattccctttg-
gatttgttttcttgtttcaaaaaa-3′; mFOX3, 5′-tccctttggatggtacctcttgtttcaa-3′.
Results
Identiﬁcation of an enhancer in the Isl1 locus with activity in the SHF
To identify enhancers within the mouse Isl1 locus, we compared
the sequences of human, mouse, and chicken Isl1 for conserved
regions using BLAST and VISTA analyses (Altschul et al., 1990; Mayor
et al., 2000) over a region spanning from −300 kb to +300 kb of
the mouse Isl1 locus. These analyses resulted in the identiﬁcation of
ten deeply conserved noncoding regions, which were each tested for
enhancer activity in transgenic embryos using the transgenic
reporter plasmid HSP68-lacZ (Kothary et al., 1989). Several of these
fragments directed consistent patterns of expression in transgenic
embryos between E8.5 and E9.5. One of the regions, referred to as
Isl1-F, was located between 3324 and 6965 bp downstream of the
translational stop codon in the mouse Isl1 gene (Fig. 1). Isl1-F was
selected for further detailed analysis because it was sufﬁcient to
direct β-galactosidase expression to the SHF, including the phar-
yngeal mesoderm and its derivatives in outﬂow tract and right
ventricular myocardium and endocardium during early heart devel-
opment (Fig. 2).To deﬁne in detail the expression directed by the Isl1-F enhancer in
vivo, we examined X-gal-stained transgenic embryos by whole-mount
and transverse section at various developmental stages. Expression of
β-galactosidase was ﬁrst seen throughout the embryonic mesoderm
and in the allantois at E7.0 (Fig. 2A, D). Expression directed by the Isl1-
F enhancer was strong in the precardiac anterior lateral mesoderm
and continued to be apparent in most of the embryonic mesoderm at
E7.75 (Fig. 2B, E). Strong expression of β-galactosidase continued in
the pharyngeal mesoderm and endoderm and in the outﬂow tract
and right ventricle at E8.5 (Fig. 2C, F). Examination of X-gal-stained
transverse sections from E8.5 transgenic embryos indicated that the
majority of cells in the outﬂow tract myocardium and the right side of
the single common ventricle were positive for β-galactosidase,
whereas most of cells on the left side of the ventricle were negative
for transgene expression (Fig. 2F), which is consistent with the
contribution of Isl1+ cells to the developing heart (Cai et al., 2003).
Similarly, at E8.75, Isl1-F transgenic embryos showed robust β-
galactosidase expression in the right ventricle but essentially no
expression in the left ventricle (Fig. 2G, H). At E9.75, expression
directedby the Isl1-Fenhancer continued to be robust in thepharyngeal
mesoderm and was also visible in the outﬂow tract and right ventricle
(Fig. 2I). This patternof lacZ expressiondirectedby Isl1-Fwas consistent
with the pattern of endogenous Isl1 mRNA expression by in situ
hybridization, albeit somewhat broader (Fig. 2J–L). Immunoﬂuores-
cence analyses of β-galactosidase and Isl1 protein expression also
showed that β-galactosidase colocalized with endogenous Isl1 protein
within the pharyngeal mesoderm and endoderm in Isl1-F transgenic
embryos at E8.5 (Fig. 2M–O). The strong β-galactosidase activity in the
heart at E8.5 and E9.75 was probably due, at least in part, to the long
half-life of the β-galactosidase protein (Thompson et al., 1991; Voon
et al., 2005), allowing cells in which Isl1-Fwas active to continue to be
marked even after endogenous expression of Isl1 had been extin-
guished (Fig. 2M–O). Taken together, these observations demonstrate
the early and speciﬁc activation of the Isl1-F enhancer in the SHF and its
derivatives in the developing heart.
A small, evolutionarily conserved fragment of the Isl1 SHF enhancer is
required and sufﬁcient for function in vivo
Within the conserved Isl1-F enhancer fragment, there are three
segments of deep evolutionary conservation, which we denoted as
CR1, CR2, and CR3 (Fig. 3A). We hypothesized that one or more of
these conserved regions were likely to be important for Isl1-F function
in vivo. Therefore, we performed a series of deletion analyses to
determine if these three conserved regions were important for SHF
activity at E8.5 (Fig. 3).
We created three deletion constructs designed to test smaller
fragments that each contained only a single conserved region
(Fig. 3A). The CR1 region was contained within Isl1-F1 (nucleotides
1–1589) and showed variable degrees of expression in transgenic
516 J. Kang et al. / Developmental Biology 334 (2009) 513–522embryos (Fig. 3C). Although Isl1-F1was sufﬁcient to direct expression
of lacZ to some regions of the mesoderm, it was not sufﬁcient for
pharyngeal mesoderm expression (arrowhead in Fig. 3C). Isl1-F2
encompassed CR2 and extended from nucleotides 1590 to 3288withinIsl1-F. Importantly, Isl1-F2 consistently directed robust expression to
the pharyngeal mesoderm in 7 of 8 transgenic embryos (Fig. 3D). Isl1-
F2 also showed activity in the lateral mesoderm, albeit less than full
length Isl1-F (Fig. 3B, D). In contrast, deletion of the 5′ end of Isl1-F to
Fig. 3. Deletion analyses of the Isl1-F enhancer identify a smaller, conserved region that is required and sufﬁcient for enhancer function in the SHF in vivo. (A) Schematic
representation of deletion constructs of the Isl1-F SHF enhancer examined in these studies. The top line depicts the organization of Isl1-F. The red boxes indicate regions of high
sequence homology between the mouse, human, and chick Isl1 genes, denoted as CR1, CR2, and CR3. The nucleotide positions of each deletion construct, relative to Isl1-F, are
indicated on the left. The mesoderm activity of each of the deletion constructs and the number of independent transgenic lines that displayed SHF activity over the total number of
lacZ+ lines are indicated in the columns to the right. (B–F) Representative transgenic embryos collected at E8.5 for each of the deletion constructs. Isl1-F (B) and Isl1-F2 (D) directed
strong and speciﬁc expression of lacZ to the pharyngeal mesoderm (arrowheads). Isl1-F1 (C) directed weak expression to the pharyngeal mesoderm compared to strong expression
to the lateral mesoderm and Isl1-F3 (E) displayed no detectable expression in the pharyngeal mesoderm. Deletion of CR2 (Δ1784–2081) in the context of Isl1-F2 to generate fragment
Isl1-F2Δ298 resulted in a complete loss of enhancer activity (F). Asterisks denote the heart in all panels.
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completely abolished transgene activity in vivo in all embryos
examined (Fig. 3E).
To determine whether CR2 was necessary for enhancer activity of
Isl1-F2, a small region (nucleotides 1784–2081) encompassing CR2,
was deleted. This Isl1-F2Δ298 transgene lacked any detectable
expression of β-galactosidase in the pharyngeal mesoderm (Fig. 3F),
indicating that CR2 was required for the activity of Isl1-F2 in the
pharyngeal mesoderm in vivo. We next wanted to determine whether
the CR2 region was sufﬁcient for pharyngeal mesoderm activity in
vivo. Therefore, we further deleted both the 5′ and 3′ ends from Isl1-F2
to create a smaller 516 bp fragment (nucleotides 1686–2201), which
included all of CR2. Interestingly, this smaller region of Isl1-F2 did not
have complete enhancer activity in the pharyngeal mesoderm at E8.5
(data not shown), suggesting that essential functional elements reside
within Isl1-F2 both inside and outside of CR2.
Isl1-F2 contains multiple, conserved Forkhead binding sites
The deletion analyses shown in Fig. 3 identiﬁed the Isl1-F2
fragment as sufﬁcient and required for enhancer activity in the
pharyngeal mesoderm in vivo. Therefore, to help identify speciﬁc
transcription factor binding sites, we analyzed the Isl1-F2 fragment forFig. 2. The Isl1-F-lacZ transgene is expressed broadly in the mesoderm and in the SHF duri
sagittal (D) or transverse (E, F) sections of X-gal-stained Isl1-F-lacZ transgenic embryos are
heart-forming anterior lateral mesoderm (hfm) and in the extraembryonic mesoderm in the
mesoderm (lm) at E7.75. (C, F) At E8.5, expression of Isl1-F-lacZ was evident in the SHF and
outﬂow tract (OFT), and right ventricle (RV). (G, H) β-galactosidase activity was restricted
mesoderm. (I) At E9.75, β-galactosidase activity from the Isl1-F-lacZ transgene expression rem
at this stage. (J–L) For comparison, whole-mount in situ hybridization with an Isl1 antise
pharyngeal mesoderm in K and L. (M–O) Immunoﬂuorescence analyses on transverse sect
antibodies show that endogenous Isl1 protein (red) colocalizes with β-galactosidase (gr
pharyngeal endoderm (pe).candidate transcription factor binding sites by comparing sequences
from multiple species. Analyses by BLAST (Altschul et al., 1990),
ClustalW (Thompson et al., 1994), and TESS (http://www.cbil.upenn.
edu/cgi-bin/tess/tess) identiﬁed three candidate binding sites for
Forkhead (FOX) transcription factors, which were highly conserved
among human, mouse, and chicken (Fig. 4A). The ﬁrst two sites (FOX1
and FOX2) were present in CR2, while the third site (FOX3) was
located outside CR2 but still within Isl1-F2 (Fig. 4A). The presence of
multiple conserved consensus Forkhead sites was interesting since
several members of the Forkhead family are known to be involved in
early heart and mesoderm development (Kume et al., 2001;
Papanicolaou et al., 2008; Seo and Kume, 2006; von Both et al.,
2004), suggesting that Isl1 might be a direct target of one or more
Forkhead transcription factors through the putative FOX sites in the
Isl1-F2 enhancer.
To determine whether the candidate FOX sites in the Isl1-F2
enhancer might represent bona ﬁde cis-acting elements, we tested
each of the three sites for binding to candidate general mesoderm and
cardiac Forkhead factors by EMSA. FoxA2 bound to all three FOX sites
in the Isl1-F2 enhancer (Fig. 4B; lanes 6, 12, and 18) as well as to a
consensus FoxA2 control site (Fig. 4B, lane 2; Overdier et al., 1994).
Binding to all four sites was efﬁciently competed by excess unlabeled
FoxA2 control probe and its unlabeled self probe, but not by mutantng early mouse embryonic development. Representative whole-mount (A–C, G–I) and
shown. (A, D) Isl1-F directed strong lacZ expression to the mesoderm at E7.0, including
allantois (al). (B, E) Isl1-F activity became more robust and more reﬁned to the lateral
its derivates in the pharyngeal mesoderm (arrowheads), pharyngeal endoderm (pe),
to the RV and was largely absent from the left ventricle (LV) at E8.75. spl, splanchnic
ained strong in the pharyngeal mesoderm (arrowhead) and was still visible in the OFT
nse probe was performed at E7.75 (J), E8.5 (K), and E9.5 (L). Arrowheads mark the
ions of Isl1-F-lacZ transgenic embryos at E8.5 using anti-Isl1 and anti-β-galactosidase
een) in SHF-derived tissues, including the pharyngeal mesoderm (arrowheads) and
Fig. 4. The Isl1-F2 enhancer contains three high afﬁnity Forkhead binding sites. (A) ClustalW and TESS analyses, comparing the sequence of the conserved enhancer region from
mouse, human, and chick, identiﬁed three conserved candidate binding sites (red boxes) for Forkhead transcription factors, denoted as FOX1, FOX2, and FOX3. (B–D) Recombinant
FoxA2, FoxC2, and FoxF1 proteins were transcribed and translated in vitro and used in EMSA with a radiolabeled double-stranded oligonucleotide encompassing the three Isl1 FOX
sites as well as control FOX sites. Lanes 1, 5, 11, and 17 in panels B–D contains reticulocyte lysate without any recombinant protein. (B) Recombinant FoxA2 efﬁciently bound to all
three Isl1 FOX sites (lanes 6, 12, and 18). Binding was speciﬁcally competed by excess unlabeled FoxA2 control probe and by unlabeled self probe, but not by a mutant version of the
probes (FOX1, lanes 7–10; FOX2, lanes 13–16; FOX3, lanes 19–22). (C) Recombinant FoxC2 bound to the FOX1 and FOX3 sites but not to the FOX2 site (lanes 6,12, and 18) and binding
to the FOX1 and FOX3 sites was speciﬁcally competed by excess control or self probe, but not by mutant probe (FOX1, lanes 7–10; FOX3, lanes 19–22). (D) Similarly, recombinant
FoxF1 protein bound to the FOX1 (lanes 6–10) and FOX3 (lanes 18–22) sites but not to the FOX2 site (lanes 12–16). Each protein bound efﬁciently to its bona ﬁde speciﬁc control probe
and was competed for binding by an excess control probe, but not by a mutant version of the probe (lanes 2–4 in panels B–D). Free probe and lysate-derived mobility shifts are
indicated.
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control site, lanes 7–10 for FOX1, lanes 13–16 for FOX2, and lanes 19–
22 for FOX3). All three Isl1-F2 FOX sites bound to FoxA2 in EMSA as
well as the FoxA2 control site, but the FOX1 site bound particularlywell (note the relative amounts of FoxA2 retarded probe compared to
free probe in each panel in Fig. 4B).
FoxC2 bound speciﬁcally to the FOX1 and FOX3 sites from Isl1-F2
(Fig. 4C, lanes 6 and 18) and this binding was efﬁciently competed by
Fig. 5. The Isl1-F2 SHF enhancer is dependent on Forkhead transcription factor binding
sites for enhancer activity in vivo. Transgenic embryos harboring Isl1-F2wild-type (wt)
transgenes (A–C) or Isl1-F2 triple FOXmutant (mut) transgenes (D–F) were collected at
E8.5 and X-gal-stained, and the lateral right-sided views of whole-mount embryos (A, B,
D, E) and transverse sections (C, F) are shown. Examples of strong (A) and weak (B)
transgenic lines harboring the wild-type Isl1-F2 transgene exhibited speciﬁc expression
in the pharyngeal mesoderm and pharyngeal endoderm, as well as in the outﬂow tract
myocardium with variable degrees of expression strength depending on the speciﬁc
transgenic line. (D, E) By contrast, embryos transgenic for the triple FOX mutant Isl1-F2
construct showed either weak or no expression in SHF derivatives and showed no
expression in the outﬂow tract. (C, F) Transverse sections of transgenic embryos with
strong expression of the wild-type Isl1-F2-lacZ transgene (C) or strong expression of the
triple FOX mutant Isl1-F2-lacZ (mut) transgene (F) show that while the wild-type
transgene was active in the pharyngeal mesoderm (arrowheads), pharyngeal
endoderm (arrows) and SHF mesoderm-derived lineages in the heart (hrt), the mutant
transgene was only weakly active in pharyngeal endoderm and showed no activity in
SHF-derived mesoderm or any of its mesodermal derivatives. Asterisks denote the heart
in panels A, B, D, and E.
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those competitors (Fig. 4C; lanes 7–10 for FOX1 and lanes 19–22 for
FOX3). The FOX1 probe was bound about as efﬁciently by FoxC2 as the
control FoxC2 site, whereas the FOX3 site was bound relatively more
weakly by this Forkhead protein in EMSA (compare bound probe to
free probe in each of the panels in Fig. 4C). In contrast to the FOX1 and
FOX3 sites, the FOX2 site was not speciﬁcally bound by FoxC2 since
binding to that element was not competed by excess unlabeled probe
(Fig. 4C, lanes 13–16). Similarly, FoxF1 bound speciﬁcally to the FOX1
and FOX3 sites in the Isl1-F2 enhancer and to a control FoxF1 site (Fig.
4D, lanes 2, 6, and 18) but FoxF1 did not bind speciﬁcally to the FOX2
site since binding to that site was not competed by unlabeled control
or self probe (Fig. 4D, lanes 13–16). Taken together, the EMSA data in
Fig. 4 show that the FOX1 and FOX3 sites from Isl1-F2 are bound
speciﬁcally by FoxA2, FoxC2, and FoxF1 and that binding to the FOX1
site was particularly strong, at least in vitro. By contrast, the FOX2 site
showed selectivity among Forkhead proteins since this site was
efﬁciently and speciﬁcally bound by FoxA2 but not by FoxC2 or FoxF1.
The Forkhead (FOX) binding sites are required for Isl1-F2 enhancer
function in vivo
To test the function of the FOX sites from the Isl1-F2 enhancer
in vivo, we introduced mutations into all three FOX sites in the
context of the Isl1-F2-lacZ transgene and determined the effect of
those mutations on enhancer function in transgenic embryos at
E8.5 (Fig. 5). The introduced mutations were identical to those used
in the EMSA analyses, which were demonstrated to completely block
the ability of those sites to compete for Forkhead protein binding even
when present in the EMSA reactions at ~50-fold excess (Fig. 4). As
expected, the wild-type Isl1-F2 enhancer directed strong (Fig. 5A, 50%
of independent transgenic events) or modest (Fig. 5B, 50% of
independent transgenic events) expression to the SHF. X-gal-staining
of transverse sections of embryos bearing the wild-type Isl1-F2
transgene showed that the wild-type enhancer directed speciﬁc
expression to the pharyngeal mesoderm and endoderm as well as to
the distal outﬂow tract (Fig. 5C). In contrast, themutant transgene had
greatly diminished or absent β-galactosidase activity (Fig. 5D–F).
Among the ﬁve transgenic embryos that harbored the FOX mutant
transgene, one showed modest expression (Fig. 5D), two showed very
weak expression (Fig. 5E) and two showed no detectable β-
galactosidase activity (not shown). Interestingly, transverse sections
of the strongest of the triple FOX mutant Isl1-F2 transgenic embryos
showed that expression of β-galactosidase was completely abolished
in the pharyngeal mesoderm and the outﬂow tract, although some
expression remained in the pharyngeal endoderm (Fig. 5F). These
results indicate that the Isl1 SHF enhancer identiﬁed in these studies
requires the conserved Forkhead binding sites for activity in the
pharyngeal mesoderm and its derivatives in vivo and strongly support
the notion that Isl1 is a direct transcriptional target of Forkhead
transcription factors in the SHF.
Discussion
Isl1 is among the earliest marker of the developing cardiac
mesoderm, and mouse embryos lacking Isl1 have profound defects in
heart development (Cai et al., 2003). Numerous studies in recent years
have highlighted the essential role of Isl1 in the transcriptional
program for SHF development (Cai et al., 2003; Cohen et al., 2007;
Dodou et al., 2004; Klaus et al., 2007; Lin et al., 2006, 2007; Park et al.,
2006; Takeuchi et al., 2005). Several direct transcriptional targets of
Isl1 have been identiﬁed, including other essential cardiac transcrip-
tion factor genes such as Mef2c and Nkx2–5 (Dodou et al., 2004;
Takeuchi et al., 2005). However, the regulation of the Isl1 gene itself,
particularly in cardiac lineages, has remained largely unresolved. An
important recent study by Evans and coworkers showed that Isl1requires β-catenin for expression in cardiovascular progenitors,
suggesting a role for canonical Wnt signaling upstream of Isl1 (Lin
et al., 2007). In addition, it was shown by chromatin immunopreci-
pitation that the Isl1 proximal promoter was bound directly by β-
catenin (Lin et al., 2007). However, other than the proximal upstream
region, these studies did not identify any cis-regulatory enhancers, and
Wnt andβ-catenin signaling alone is unlikely to account for the cardiac
progenitor expression of Isl1during development. In the present study,
we identiﬁed an enhancer from themouse Isl1 genewith activity in the
SHF, which allowed us to identify Isl1 as a direct transcriptional target
of Forkhead transcription factors in SHF-derived mesoderm.
The activity of the Isl1 enhancer described here closely matched
the endogenous pattern of Isl1 expression in vivo, although the
pattern of β-galactosidase expression presented here is somewhat
broader than the pattern of endogenous Isl1 mRNA or Isl1 protein
(Fig. 2), which is probably due to the longer half-life of β-galactosidase
520 J. Kang et al. / Developmental Biology 334 (2009) 513–522(Thompson et al., 1991; Voon et al., 2005). Importantly, a previously
described Isl1-nlacZ knock-in mouse showed a similarly broad pattern
of nlacZ expressionwhen compared to the pattern of expression of the
endogenous Isl1 transcript (Sun et al., 2007). The expanded Isl1
expression domain deﬁned by the knock-in studies included the
outﬂow tract, aorta, pulmonary artery, atrial septum, venous valves,
cardiac ganglia, and the sinoatrial and atrioventricular nodes (Sun
et al., 2007). Isl1-F also shows expression in the outﬂow tract, aorta,
pulmonary artery, and atrial septum, but it does not have activity in all
the domains (e.g. the motor neurons in the neural tube) seenwith the
Isl1-nlacZ knock-in allele (Sun et al., 2007). Isl1 is expressed broadly in
many regions other than the SHF, including the ventral neural tube
and the visceral endoderm (Pfaff et al., 1996), and the expression of
the lacZ knock-in allele reﬂects this broad pattern of expression (Sun
et al., 2007). By contrast, the activity of the enhancer described here is
restricted to the SHF, including pharyngeal and splanchnic mesoderm
and pharyngeal endoderm. The function of Isl1-F as a modular
enhancer with activity restricted to the SHF is consistent with the
more restricted expression pattern of Isl1-F-lacZ enhancer compared
to Isl1-nlacZ knock-in allele. Thus, our results demonstrate that the
Isl1-F enhancer faithfully recapitulates a subset of the endogenous
Isl1 pattern and suggest that this enhancer, or the smaller Isl1-F2,
may be a useful tool for marking the SHF component of the Isl1
expression pattern.
Evolutionary conservation of Isl1-F2 sequence
Evolutionary pressure has produced many radical changes in the
cardiopulmonary systemof vertebrates, resulting in addition of several
components to the primitive chordate ancestor to make a vertebrate
heart (Fishman and Chien, 1997). One essential addition is a second
chamber that is designed for generating high systemic blood pressure.
Further organization of the original tubular heart into separate
systemic and pulmonary circulations was accomplished by separation
of ventricles and atria by septa (Bishopric, 2005). Fish have a simpler,
two-chambered heart that provides both oxygenation and systemic
circulation, while birds and mammals have a four-chambered heart
including two atria and two ventricles that allow separate ﬂow of
oxygenated and deoxygenated blood, and a complete division of the
systemic and pulmonary circulations (Bishopric, 2005). Indeed, the
right ventricle and corresponding separate outﬂow tracts are relatively
recent additions to the vertebrate heart, and these structures are
largely derived from cells of SHF origin, particularly from the anterior
regions in the pharyngeal mesoderm (Abu-Issa and Kirby, 2007; Abu-
Issa et al., 2004; Black, 2007; Buckingham et al., 2005; Kelly and
Buckingham, 2002). Therefore, it is interesting to note that the Isl1-F2
enhancer, which is active in the SHF, is highly conserved among
amniotes but not conserved in lower vertebrates such as frogs and
ﬁshes (Supplemental Material, Fig. S1).
The conservation of the Isl1-F2 sequence between birds and
mammals, together with the lack of sequence conservation with frogs
and ﬁshes, suggests that the Isl1-F2 enhancer may have evolved in
amniotes as Isl1 function was co-opted for heart development.
Consistent with this notion, no cardiac phenotype was reported
when Isl1 expression was abolished by morpholino knockdown in
zebraﬁsh, and the expression of Isl1 in zebraﬁsh does not occur in
heart-forming regions (Korzh et al., 1993; Segawa et al., 2001).
Likewise, a scan for ultra-conserved enhancers from the zebraﬁsh Isl1
locus, resulted in the identiﬁcation of three distal enhancers with
activity in motor and sensory neurons, but no cardiac or cardiac
progenitor enhancers were identiﬁed (Uemura et al., 2005). While
these observations do not rule out a role for Isl1 in heart development
in lower vertebrates, together, they support the idea that a role for Isl1
in heart development may have co-evolved with the development of
the complex cardiopulmonary system found in birds and mammals. If
this is the case, then the evolutionary adaptation of Isl1 to heartdevelopment would likely have occurred through changes in
noncoding sequences, resulting in the acquisition of enhancer
elements with activity in the SHF in birds and mammals. It is
attractive to speculate that the evolution of the Isl1-F2 enhancer, and
its regulation by Forkhead transcription factors, may have played an
important role in the evolution of the right ventricle. Future studies
focused on the deletion of the Isl1-F2 enhancer from the germline of
mice will be important to determine if this cis-acting element is
required for heart development in vivo.
Forkhead-dependent activation of Isl1 in the SHF
The studies presented here demonstrate a clear requirement for
conserved consensus Forkhead binding sites for Isl1-F2 enhancer
function in SHF-derivedmesoderm in transgenic embryos (Fig. 5). Our
results show that each of the three conserved Forkhead (FOX)
transcription factor binding sites in Isl1-F2 was efﬁciently bound in
EMSA by at least one of the Forkhead proteins examined, including
FoxA2, FoxC2, and FoxF1 (Fig. 4). Each of these members of the
Forkhead family is an excellent candidate for direct regulation of Isl1
in vivo, based on expression and functional data.
Mice lacking both the Foxc1 and Foxc2 genes show severe defects
in right ventricle and outﬂow tract formation, and expression of both
genes overlaps the expression of Isl1 in the SHF beginning at the
cardiac crescent stage at E7.75 (Seo and Kume, 2006). Importantly,
Isl1 expression in Foxc1/Foxc2 double mutants was reduced in the
pharyngeal and splanchnic mesoderm at E8.5 but was unaffected in
the pharyngeal endoderm (Seo and Kume, 2006). These previous
results are consistent with our observation that mutation of the FOX
sites in the Isl1-F2 enhancer completely abolished enhancer activity in
the pharyngeal mesoderm, but did not completely eliminate expres-
sion in the pharyngeal endoderm (Fig. 5).
Foxa2 is expressed in the pharyngeal endoderm and the pheno-
types in Foxa2 null mice demonstrate an essential role for this factor in
endoderm development (Ang and Rossant, 1994; Weinstein et al.,
1994). Interestingly, Foxa2 mutant chimeras in which Foxa2 expres-
sion was rescued in the visceral endoderm survive longer than Foxa2
null embryos and died around E9.5 with severe heart defects even
though expression of Foxa2 was not detected in cardiac mesoderm
(Dufort et al., 1998). More recent studies have shown that Foxa2 is
expressed in SHF-derived pharyngeal mesoderm where it directly
regulates Tbx1 (Hu et al., 2004; Maeda et al., 2006; Yamagishi et al.,
2003). Thus, it remains a possibility that FoxA2 regulates Isl1
expression in the SHF by binding to the FOX sites in the Isl1-F2
enhancer at an early time during cardiac mesoderm speciﬁcation, and
indeed, our EMSA results showed that FoxA2 bound speciﬁcally to
each of the three FOX sites in Isl1-F2.
Foxf1 is expressed broadly in the embryonic and extraembryonic
mesoderm, beginning at gastrulation (Kalinichenko et al., 2003;
Mahlapuu et al., 2001; Peterson et al., 1997). Eventually, Foxf1
expression becomes more restricted to the lateral mesoderm and
then to septum transversummesenchyme and the visceral mesoderm,
which ultimately gives rise to mesenchymal cells of gut-derived
organs (Kalinichenko et al., 2003; Mahlapuu et al., 2001; Peterson et
al., 1997). These expression data suggest that if FoxF1 regulates Isl1-F2,
it is likely to do so early in mesodermal development, when its broad
expression encompasses the Isl1-F2-lacZ expression pattern. However,
FoxF1 is unlikely to control enhancer activity via direct binding in the
splanchnic and pharyngeal mesoderm at later times in development.
Interestingly, Foxh1 null mice fail to form AHF-derived structures,
including the outﬂow tract and right ventricle, but normally form
inﬂow and atrial regions (von Both et al., 2004). Notably, loss of Foxh1
did not affect Isl1 expression in the splanchnic and pharyngeal
mesoderm (von Both et al., 2004). Consistent with this earlier report,
we did not observe any signiﬁcant binding of FoxH1 to any of
candidate FOX sites in the Isl1-F2 (data not shown). Together, these
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SHF development.
Although it is not clear exactly which Forkhead transcription
factor(s) activate Isl1-F2, it is attractive to speculate that one or more
Forkhead proteins may function in the SHF in a manner analogous to
FoxA2 function in the endoderm (Cirillo et al., 2002; Cirillo and Zaret,
1999). In that lineage, FoxA2 functions in cooperation with the zinc
ﬁnger transcription factor GATA4 by binding directly to the albumin
gene to open chromatin and allow for transcriptional activation
(Cirillo et al., 2002; Cirillo and Zaret, 1999). Interestingly, the Isl1-F2
enhancer has a deeply conserved GATA binding site, which exhibited
robust binding to GATA4 in EMSA (data not shown). Thus, it will be
interesting to test whether a Forkhead factor functions in cooperation
with GATA4 upstream of Isl1 in the SHF in a manner analogous to
FoxA2-GATA4 in the endoderm.
Isl1 SHF enhancer-directed transgenes as tools to mark Isl1+
progenitor cells
Isl1-expressing cardiac progenitors contribute to three major
cardiac lineages, including cardiomyocytes, smooth muscle, and
endothelial cells (Laugwitz et al., 2005; Moretti et al., 2006). These
multipotent progenitor cells, which are prevalent in the early embryo,
persist into adulthood and are found sparsely within the adult
myocardium (Laugwitz et al., 2005; Moretti et al., 2006). Although
postnatal Isl1+ cardiac progenitors are not prevalent, they can be
isolated from embryos or from adult myocardium and expanded ex
vivo (Laugwitz et al., 2005; Moretti et al., 2006), suggesting that these
cells may be useful for therapeutic applications. Likewise, human or
mouse ES cells can be cultured under conditions that will promote the
formation of these multipotent Isl1+ progenitor cells (Laugwitz et al.,
2005; Moretti et al., 2006; Qyang et al., 2007). Importantly, however,
Isl1 expression alone is not sufﬁcient to identify ES cells or iPS cells
with cardiac progenitor potential, since Isl1 expression is associated
with many lineages other than those derived from cardiogenic
progenitors, including neuronal lineages, oral epithelium, inner ear,
thalamus, pituitary cells, pancreatic β cells and distal tubular cells of
the kidney (Ahlgren et al., 1997; Dong et al., 1991; Mitsiadis et al.,
2003; Nakagawa and O'Leary, 2001; Pfaff et al., 1996; Radde-Gallwitz
et al., 2004).
It has been necessary to use a combination of markers, including
Flk1, Isl1, and Nkx2–5, to accurately identify progenitor cells that have
cardiovascular potential (Moretti et al., 2006). Alternatively, trans-
genes, under the control of modular transcriptional enhancers, with
expression restricted to the SHF or the AHF could be used to mark
these multipotent cardiovascular progenitors. Indeed, a GFP transgene
under the control of regulatory elements from the Mef2c gene
accurately marks Isl1+ progenitor cells with cardiovascular potential
(Qyang et al., 2007). However, the Mef2c-AHF enhancer is a direct
transcriptional target of Isl1 (Dodou et al., 2004), and is, therefore,
downstream in the hierarchy controlling the development of these
cells. In this regard, the Isl1-F2-lacZ transgene described here may be a
useful reagent for marking multipotent cardiovascular progenitors by
combining the early expression of endogenous Isl1 with expression
that is restricted to a subdomain of the endogenous Isl1 expression
pattern. It will also be interesting to determine what role, if any,
Forkhead proteins play in the differentiation of Isl1+ cells to cardiac,
smooth muscle, and endothelial lineages.
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